Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
(sofosbuvir velpatasvir voxilaprevir)
82 results
  • Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C. [Review]
    Infect Drug Resist 2019; 12:2259-2268Childs-Kean LM, Brumwell NA, Lodl EF
  • The treatment of chronic hepatitis C has been revolutionized with the introduction of direct-acting antivirals (DAAs). However, some patients are not cured with first-line treatment. Sofosbuvir/velpatasvir/voxilaprevir is a fixed-dose combination of a polymerase inhibitor, an NS5A inhibitor, and a protease inhibitor with activity against strains of the hepatitis C virus that show resistance to ot…
  • Management of HCV patients in cases of direct-acting antiviral failure. [Journal Article]
    Expert Rev Gastroenterol Hepatol 2019; 13(9):839-848Hayes CN, Imamura M, Chayama K
  • Introduction: Over 70 million people are infected with hepatitis C virus (HCV), increasing the risk of cirrhosis and hepatocellular carcinoma. Areas covered: Since the approval of the first interferon-free direct-acting antiviral (DAA) therapy in 2011, a number of DAAs have been approved, and HCV is now considered curable. Until recently, however, there were no clear guidelines on how to re-treat…
  • High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world. [Journal Article]
    J Hepatol 2019; 71(5):876-888Pérez AB, Chueca N, … GEHEP-004 Study Group
  • CONCLUSIONS: In our study, we show how resistance-guided retreatment in conjunction with an interpreted report allows patients to achieve SVR rates close to 90%. We hypothesize that SVR rates may even be improved if resistance data are discussed between experienced virologists and treating clinicians. We believe that our data may be relevant for countries where the access to new DAA combination regimens is limited.
New Search Next